Major deal with Leo Pharma sends Union Therapeutics into new areas
The team behind Union Therapeutics enters both psoriasis and oral treatments through its new big transaction with Leo Pharma, markedly boosting the company's potential, says CFO Morten Boesen.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY DANIEL FRANK CHRISTENSEN & IDA JACOBSEN
Union Therapeutics has previously in-licensed medicinal rights, but the company's deal with Leo Pharma for the drug orismilast still breaks new ground for the Danish biotech group, established in 2011 – not only because the agreement, with a combined value of DKK 1.3 billion, is the firm's largest to date.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
